IMAGENEBIO INC
IMANASDAQ🏆 #4425 by market capUS Equity
$287.64▼ $2.33 (−0.81%)
Simulated priceTrack IMA
Get earnings, price moves & breaking news on Telegram
24h▼ 0.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$53M
Small Cap
📈Revenue Growth (YoY)
-77.1%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
72
Fair
No chart data available for IMA.
Trading Snapshot
- Day Range
- $284.35 – $292.92
- 52-Week Range
- $3.94 – $9.10
- Volume
- $2.70B
- Avg Volume
- $2.60B
- Shares Outstanding
- 11.3M
- Next Earnings
- Nov 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $800,000
- Last Q Revenue
- $184,753
- P/E Ratio
- -0.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.25
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +693.1%
Why Investors Own IMA
- ✓High-growth profile — revenue up +30.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 70% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
IMAGENEBIO INC
IMAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$800K▼ −77.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-29.1%▼ −151.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$48M▲ +30.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$48M▲ +4.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.2M▲ +693.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$25M▼ −$7M YoY
StockOtter · stockotter.spaceAbout IMAGENEBIO INC
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100
Analyst Price Target
ⓘAverage Target
$318.27
▲ +10.7% Upside
High Target$389.77
Low Target$280.23
Based on 32 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
IMAGENEBIO INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift IMA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
IMAGENEBIO INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.